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Metabolism of bladder cancer represents a key issue for cancer research. Several metabolic altered
pathways are involved in bladder tumorigenesis, representing therefore interesting targets for therapy.
Tumor cells, including urothelial cancer cells, rely on a peculiar shift to aerobic glycolysis-dependent
metabolism (the Warburg-effect) as the main energy source to sustain their uncontrolled growth and
proliferation. Therefore, the high glycolytic flux depends on the overexpression of glycolysis-related
genes (SRC-3, glucose transporter type 1 [GLUT1], GLUT3, lactic dehydrogenase A [LDHA], LDHB, hexok-
inase 1 [HK1], HK2, pyruvate kinase type M [PKM], and hypoxia-inducible factor 1-alpha [HIF-1a]),
resulting in an overproduction of pyruvate, alanine and lactate. Concurrently, bladder cancer metabolism
displays an increased expression of genes favoring the pentose phosphate pathway (glucose-6-phosphate
dehydrogenase [G6PD]) and the fatty-acid synthesis (fatty acid synthase [FASN]), along with a decrease of
AMP-activated protein kinase (AMPK) and Krebs cycle activities. Moreover, the PTEN/PI3K/AKT/mTOR
pathway, hyper-activated in bladder cancer, acts as central regulator of aerobic glycolysis, hence con-
tributing to cancer metabolic switch and tumor cell proliferation.
Besides glycolysis, glycogen metabolism pathway plays a robust role in bladder cancer development. In
particular, the overexpression of GLUT-1, the loss of the tumor suppressor glycogen debranching enzyme
amylo-a-1,6-glucosidase, 4-a-glucanotransferase (AGL), and the increased activity of the tumor pro-
moter enzyme glycogen phosphorylase impair glycogen metabolism. An increase in glucose uptake,
decrease in normal cellular glycogen storage, and overproduction of lactate are consequences of
decreased oxidative phosphorylation and inability to reuse glucose into the pentose phosphate and de
novo fatty acid synthesis pathways. Moreover, AGL loss determines augmented levels of the serine-to-
glycine enzyme serine hydroxymethyltransferase-2 (SHMT2), resulting in an increased glycine and
purine ring of nucleotides synthesis, thus supporting cells proliferation.
A deep understanding of the metabolic phenotype of bladder cancer will provide novel opportunities
for targeted therapeutic strategies.
 2016 Elsevier Ltd. All rights reserved.Introduction
Muscle-invasive bladder cancer (BC) is the 9th most common
cause of death worldwide, and the 4th most common type of can-
cer among men in developed countries [1]. The poor survival of BC
patients depends on an intrinsic biologic aggressiveness of this
tumor and a peculiar radio- and chemo-resistance. Therefore,
efforts to deeply understand the pathogenic mechanisms that
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targets for therapy are strongly suggested.
Cancer development and progression is characterized by a
unique reprogramming of energy metabolism, required to sustain
highly proliferating cancer cells. Hence, understanding cancer
metabolism represents a major topic of cancer research.
Bladder cancer has profound metabolic abnormalities. Several
altered metabolic pathways play a role in bladder tumorigenesis.
Moreover, metabolomics contributed substantially in understand-
ing relevant alterations of catabolic and anabolic metabolic
processes impaired in cancer, through the identification of
tumor-specific metabolic biomarkers with a potential diagnostic,
prognostic or predictive value [2]. Metabolomics studies identified
various metabolites of diverse metabolic pathways (glucose, lipid,
amino acid, nucleotide metabolites) as probable biomarkers for BC
[3].
In this review we retraced the main metabolic pathways
involved in the pathogenesis of bladder cancer.Glucose metabolism pathway
A peculiar shift to aerobic glycolysis-dependent metabolism
(the Warburg-effect) is the hallmark of tumor cells, including BC.
Glucose catabolism produces: (1) energy in the form of ATP
(glycolysis); (2) reducing equivalents in the form of NADH (anaer-
obic glycolysis); (3) intermediate metabolites used as precursors
for the biosynthesis of non-glucidic compounds (amino acids and
lipids).
Glycolysis (anaerobic degradation of glucose to pyruvic acid) is
the binding process of glucose utilization for energy production.
Glycolytic pyruvate can be transformed/reduced to lactic acid in
the cytoplasm (anaerobic conditions), or oxidized in the mitochon-
dria (via tricarboxylic acid [TCA] cycle) into carbon dioxide and
water (aerobic status). Glucose can also be metabolized with
non-energy purposes, via the pentose phosphate cycle (PPP) to
produce pentoses necessary for the synthesis of nucleotides and
nucleic acids, and most of the NADPH required to promote reduc-
tive processes (i.e. fatty acids biosynthesis).
Unlike healthy human tissues, cancer cells metabolism is
marked by a peculiar dependence on anaerobic breakdown of glu-
cose (glucose fermentation into lactate), reduced AMPK and TCA
activity, non-energy utilization of glucose through the PPP, and
increased fatty acids synthesis even under normoxic conditions
for mitochondrial oxidative phosphorylation. This neoplastic pref-
erential metabolic switch to anaerobic glycolytic flux (instead of
oxidative phosphorylation) in normoxia is termed ‘‘aerobic glycol-
ysis” or Warburg effect [4]. Glycolysis, although less efficient than
mitochondrial respiration in energy yield, allows obtaining inter-
mediates of other key metabolic pathways. Hence, glucose is
diverted from oxidative phosphorylation (resulting in less energy
yield due to reduced ATP production) towards the biosynthesis of
macromolecular precursors (acetyl-CoA for fatty acids, glycolytic
intermediates for non-essential amino acids, and ribose for nucleo-
tides) required to sustain cell growth and division [5]. Therefore,
cancer metabolism is profoundly altered to support the demands
of proliferating tumor cells. Several alterations in metabolic genes
directly or indirectly involved in the Warburg-effect and support-
ing a glycolytic profile are implicated in cancer progression, includ-
ing over-expression of glucose transporters [6], up-regulation of
both oxidative and non-oxidative branches of the PPP (via
increased activity of glucose-6-phosphate-dehydrogenase [G6PD]
and transketolase-like-1 [TKTL1] protein, respectively) [7],
increased ATP citrate lyase (ACL) activity (key enzyme linking glu-
cose metabolism to lipid synthesis, releasing acetyl-CoA from
citrate) [8].Moreover, the high lactate amount and subsequent acidification
due to cancer cells reliance on glycolytic metabolic shift might pro-
mote carcinogenesis, favoring immune escape, acid-mediated
matrix degradation, invasiveness and metastasis, and chemo-
radio-therapy resistance [9,10].
The Warburg effect is strongly implicated in BC, being associ-
ated with aggressive tumor behavior. In particular, the main alter-
ations in glucose metabolism reported in urothelial bladder cancer
patients include:
Stimulated GLUT-1 activity
As discussed in more detail later, glucose transporters (GLUT)
activity undergoes relevant changes in tumors, including BC, since
cancer cells survival and proliferation is strictly associated with
glucose uptake [11].
Up-regulation of glycolysis
Three key rate-limiting enzymes control glycolysis: hexokinase
(HK), 6-phosphofructokinase (PFK) and pyruvate kinase (PK). First,
HK phosphorylates glucose in glucose-6-phosphate; the HK type II
isoenzyme is over-expressed in cancers. PFK catalyzes the phospho-
rylation of fructose-6-phosphate to fructose-1,6-bisphosphate, a
key regulatory step of the glycolytic pathway. PFK activity is ele-
vated in cancer cell lines particularly in response to proliferating
signals secondary to activation of RAS and SRC or HIF-1a. PK (espe-
cially PK type M2) controls the final step of glycolysis, dephospho-
rylating phosphoenolpyruvate to generate pyruvate and ATP,
therefore contributing to the glycolytic flux in PKM2 – expressing
cancer cells. Given the up-regulation of glycolytic pathway
enzymes, glycolytic inhibitors could be an effective anticancer
strategy, but there are some concerns with their use (low potency,
low selectivity for the target, resulting in significant toxicity) [12].
A proteomic analysis of isobaric tags for relative and absolute
quantification (iTRAQ) identified down-regulation of PFK (along
with proliferating cell nuclear antigen [PCNA], PKM2, HK-1 and cell
surface glycoprotein [CD146]) in bladder cancer after Bifidobac-
terium infantis-mediated HSV-TK/GCV suicide gene treatment,
indirectly demonstrating the role of PKF in promoting BC carcino-
genesis [13]. Interestingly, in bladder cancer PFK protein expres-
sion levels significantly decreased with increased tumor stage
and grade [14–16], assuming a role in early phases of
carcinogenesis.
Increased pyruvate metabolism, and augmented lactated and alanine
production
Pyruvate is the terminal product of anaerobic glycolysis. Under
physiological aerobic conditions, pyruvate is oxidized to carbon
dioxide to efficiently produce energy, and serves as a precursor
for different biosynthetic pathways. As previously stated, tumor
cells exhibit a distinctive high glycolytic flux even in conditions
of adequate availability of oxygen to perform mitochondrial oxida-
tive phosphorylation for the Warburg effect.
Accordingly, BC shows a shift in pyruvate metabolism, which is
more pronounced in advanced disease stages. BC progression from
a less to a highly invasive stage is associated with increased of
pyruvate levels [16].
Interestingly, pyruvate becomes the main energy fuel (instead
of glucose) for highly proliferating BC cells, which consume most
of the available pyruvate [16]. This can explain the down-
regulation of pyruvic acid reported in BC cell lines, which could
be related to high synthetic rate of lactate [17].
Therefore, in cancer cells pyruvate is usually reduced to lactate.
Lactate dehydrogenase (LDH) catalyzes the conversion of pyruvate
to lactate, as it converts NADH to NAD+. Pyruvate is, in fact, used as
acceptor of reducing equivalents of NADH(H+) that are formed in
the oxidative reaction of the glyceric aldehyde-3-phosphate. If
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up to run out. The continuous oxidation of NADH(H+) in the
reaction catalyzed by LDH allows the glycolytic flux.
Cancer cells rely on fermentative glycolysis, where LDH isoform
A converts the majority of glucose stores into lactate regardless of
oxygen availability, shifting use of glucose from simple energy pro-
duction to the promotion of enhanced cell growth [18]. Bladder
cancer cells showed an over-production of lactate, with lactate
levels rising concurrent to progression to highly proliferative stage
[16]. LDH-A over-expression has been demonstrated to promote
cell proliferation, invasion and migration in invasive bladder can-
cer cell line in vitro. LDH-A seemed to promote malignant progres-
sion by stimulating epithelial-to-mesenchymal transition (EMT)
and conferring stemness in muscle-invasive bladder cancer [19].
Consistent with these data, metabolomic analyses revealed up-
regulation of glycolysis-related metabolites (enhanced acid lactic
production), and a corresponding down-regulation of TCA-related
metabolites (reduced citric acid synthesis) [3].
The lactate is extruded to the extracellular space by the action
of monocarboxylate transporters (MCTs) that play a crucial role
in regulating intracellular pH homeostasis. MCT1 and MCT4 are
involved in the metabolic reprogramming of cancer cells, con-
tributing to BC aggressive behavior. The immunohistochemical
analysis of MCT1 and MCT4 expression in BC tumor cells revealed
a diffuse membranous staining (while normal urothelial cells
showed negative or weak staining), which correlated with poor
overall survival and poor recurrence-free survival, respectively
[20]. Of note, the expression of MCTs within bladder tumor shows
peculiar patterns, which differ from tumor cells to tumor stroma
and from hypoxic areas to normoxic regions. In particular, a signif-
icant decrease in MCT1 and MCT4 positivity occurred from nor-
moxic to hypoxic regions, and a correlation between MCT4
concomitant staining in hypoxic tumor cells and in the tumor
stroma and MCT1 positivity in normoxic tumor cells with poor
prognosis and chemoresistance was observed [21].
Interestingly, up-regulation of MCT1 and MCT4 expression has
been described also in cancer-associated fibroblasts (CAFs), which
undergo aerobic glycolysis and lactate over-production providing
energy for supporting BC cell growth. This corroborates the essen-
tial role of tumor microenvironment in sustaining tumor prolifera-
tion and invasion [22].
Moreover, BC tissues express higher levels of the ABCC3 (ATP-
binding cassette, subfamily C, member 3) transporter compared
to normal urothelium, with a positive correlation with LDHA
expression, advanced BC stage and poor overall survival. Therefore,
ABCC3 could be another potential prognostic biomarker and
promising target for BC therapy [23].
The elevated lactate production creates an acidic extracellular
environment that is thought to promote tumor invasion and meta-
static spread by exerting an inhibitory action on anticancer
immune effectors [24,10].
Pyruvate can also be used in biosynthetic pathways. Instead,
part of pyruvate derived from anaerobic glycolysis can be con-
verted to alanine in a process (trans-deamination) catalyzed by
the enzymes glutamate dehydrogenase and glutamic-pyruvate
transaminase (GPT). This reaction requires NADPH(H+) to be con-
verted into NADP+. The carbon skeleton of alanine may be then
used for gluconeogenesis, while the amino group can be incorpo-
rated in the urea cycle. The production of alanine has been
reported to be enhanced in highly invasive bladder cancer cells,
while the levels of GPT are decreased [16]. The conversion of pyru-
vate to lactate or alanine is coupled with the oxidation of NADH/
NADPH to NAD+/NADP+. Therefore, the lactate/alanine ratio is an
indicator of the cell’s redox state, reflecting the equilibrium
between those two intermediates. The lactate/alanine ratio is
higher in advanced BC stage, suggesting that cancer progressionis associated with higher oxidative stress due to increased
pyruvate metabolism and lactate production [16].
Increased expression of 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (PFKFB3)
The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases
(PFKFB1-4) family encompasses bifunctional proteins that are
involved in both the synthesis (6-phosphofructo-2-kinase activity)
and degradation (fructose-2,6-biphosphatase activity) of fructose-
2,6-bisphosphate (F2,6BP), a potent regulatory molecule that acti-
vates 6-phosphofructo-1-kinase (PFK-1), thus controlling
glycolysis.
PFKFB3, which has a high ratio of kinase to phosphatase activ-
ity, is over-expressed in human cancers, regulated by HIF-1a, Akt
and PTEN, and stimulates the survival and growth of several malig-
nancies [25]. An inhibitor of PFKFB3 (3PO) demonstrated to reduce
BC cell lines proliferation, indirectly suggesting the role of PFKFB3
in BC progression [26].
Over-expression of steroid receptor coactivator-3 (SRC-3)
SRC-3 is overexpressed and/or amplified in various cancer
types, both steroid (where it exerts a steroid receptor coactivator
function) and non-steroid targeted tumors, including BC [27,28].
Zhao and colleagues demonstrated a correlation between SRC-3
overexpression and increased BC cell proliferation, assuming a role
of SRC-3 in reprogramming cancer cell metabolism. In fact, SRC-3
hyper-expression caused over-expression of genes involved in
hypoxia-induced glycolysis (HIF1a-target genes, including glut1
and pgk1), thus favoring BC development via enhanced glycolytic
rate [29].
Increased pentose phosphate pathway: up-regulation of TKTL1 protein
Transketolase enzyme reactions are crucial steps of the non-
oxidative part of the PPP, allowing oxygen-independent glucose
conversion to ribose for nucleic acid synthesis and generating
reduced NADPH required for synthesis reactions in tumor cells
[30].
Langbein et al. reported a correlation between TKTL1 over-
expression and invasive behavior of colon and urothelial cancer
leading to poor patient survival [31]. TKTL1 upregulation in tumors
leads to increased, oxygen-independent glucose catabolism and a
lactate-dependent matrix degradation. Several transketolase inhi-
bitors have demonstrated to dramatically inhibit cell proliferation
and suppress tumor growth in preclinical cancer cells models
[32,33], supporting TKTL1 as a potential target for anticancer
therapy.
Indirect evidence of the pro-carcinogenic role of PPP hyperacti-
vation comes from the demonstration of the inhibitory activity of
zoledronic acid on the G6PD enzyme (through mitigation of the
Ras-TAp73-G6PD pathway), resulting in the inhibition of the PPP
and BC cell proliferation [34].
PI3K/AKT/mTOR pathway
Aberrant activation of the PI3K-Akt-mTOR pathway is impli-
cated in bladder carcinogenesis. In particular, activating mutations
can involve PI3K a-subunit (PIK3CA), Akt1, and TSC1, while inacti-
vation of PTEN (loss of heterozygosity on chromosome 10q,
homozygous deletion of the PTEN locus, and occasional inactivat-
ing mutations in the PTEN coding region) can occur in approxi-
mately 30% of BC, correlating with poor outcomes [35–37]. In
addition, inactivation of both p53 and PTEN may promote BC inva-
siveness via up-regulation of mTOR signaling, with a correlation
with aggressive disease and poor survival in human urothelial
tumors [38].
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of cancer cells energy metabolism through the fundamental role of
Akt (the ‘‘Warburg kinase”) that stimulates aerobic glycolysis [39].
Activation of the oncogenic kinase Akt
The serine/threonine kinase Akt is commonly activated in can-
cer cells, acting as an oncogene promoting cell survival. Frequently,
Akt hyper-activation can indirectly result from amplification of the
upstream Akt activator phosphatidylinositide-3-kinase (PI3K), or
deletion of the PI3K inhibitor PTEN.
Akt exerts a direct influence on glucose metabolism by promot-
ing the shift to aerobic glycolysis, rendering cancer cells dependent
on glucose consumption and aerobic glycolysis for growth and sur-
vival, thus contributing to a more aggressive cancer behavior [40].
Several molecular mechanisms are implicated in Akt-dependent
shift to aerobic glycolytic metabolism:
 Akt directly stimulates glycolytic enzymes such as glucose
transporters, HK, and LDH [39].
 Activated Akt impairs the ability to induce fatty acid oxidation
in response to glucose deprivation [41].
 mTOR (downstream effector of Akt) induces the expression of
glycolytic enzymes, including GLUT1, LDHB, HK2 and PKM2
[42,43].
 mTOR directly stimulates the translational machinery by phos-
phorylating eIF4E binding proteins (eIF4E-BPs) and ribosomal
protein S6 kinases (S6K), enhancing expression levels of gly-
colytic proteins.
 mTOR complex 1 enhances the normoxic upregulation of the
HIF-1a transcription factor, inducing the expression of genes
involved in glycolysis [44].
Hyper-expression of miR-21
MicroRNAs (miRNAs) are a class of endogenous non-coding
single-stranded RNA molecules, usually 17–27 nucleotides in
length, which modulate gene expression post-transcriptionally,
by binding to the 30 untranslated regions of target messenger RNAs
(mRNAs) of protein-coding genes. miRNAs are implicated in vital
cellular processes: control of normal development, cell growth,
differentiation and apoptosis [45].
Altered miRNAs expression plays a crucial role in cancer devel-
opment [46]. Of note, aberrant miRNAs expression regulates aero-
bic glycolysis [47]. Several genome-wide profiling analyses
identified specific miRNAs alterations occurring in BC [48–51].
Among these, miR-21 hyper-expression has a carcinogenic role in
BC, inducing cell proliferation by inhibiting PTEN expression and
promoting AKT hyperactivation [52]. Moreover, miR-21 expression
level has been described to positively correlate with expression of
key aerobic glycolytic genes (GLUT-1, GLUT-3, LDHa, LDHB, PKM2,
HK1 and HK2) via the induction of PI3K/AKT/mTOR pathway,
strongly suggesting that miR-21 is involved in aerobic glycolysis
switch (Fig. 1). Therefore, miR-21 inhibition may impair high gly-
colysis levels in bladder cancer cells via the miR-21/PTEN/AKT/
mTOR cascade [53].
Glycogen metabolism pathway
Cancer cells undergo specific metabolic reprogramming in
response to the hypoxic environment of solid tumors.
Besides aerobic glycolysis, which has a fundamental role in pro-
viding energy and multiple intermediates critical for cell prolifera-
tion, glycogen metabolism is altered in tumor cells.
Glycogen, a highly branched polysaccharide composed of many
monomers of alpha-glucose containing both a-1,4 and a-1,6 glyco-
sidic linkages (the latter at branch points), is the main storage form
of glucose in human tissues (liver, skeletal muscles, heart), sincethe tissue accumulation of monosaccharides would create an
untenable osmotic pressure. The enzymatic processes of glycogen
synthesis and breakdown are subjected to a complex and delicate
regulation system sensitive to variables metabolic conditions, in
order to adapt reserves to the organism demands. This is made
possible primarily through the differentiation of biosynthetic
(glycogen synthesis) and catabolic (glycogenolysis) pathways,
and thanks to the regulating the activity of two fundamental
enzymes: glycogen phosphorylase and glycogen synthase.
Glucose enters the neoplastic urothelial cell mainly through
glucose transporter type 1 (GLUT-1). Intracellular glucose is con-
verted to glucose-6-phosphate (G6P) by hexokinase and trans-
formed in glucose-1-phosphate (G1P) by the serine enzyme
phosphoglucomutase. Phosphoglucomutase requires catalytic quanti-
ties of glucose-1,6-bisphosphate, derived from the phosphoryla-
tion of glucose-1-phosphate by phospho-glucokinase. G1P reacts
with uridine triphosphate (UTP) to form uridine-diphosphate-
glucose (UDPG) and inorganic pyrophosphate (PPi), which is in
turn demolished into two molecules of inorganic phosphate (Pi)
making the reaction irreversible. The first reaction is catalyzed by
the UDPG pyrophosphorylase, while the second by the enzyme
pyrophosphatase. UDPG is the immediate precursor for glycogen
synthesis. Glycogen synthase catalyzes the elongation of glycogen
chains by incorporating glucose residues of UDPG to the hydroxyl
at C4 of the terminal residue of the growing glycogen chain form-
ing an a-1,4 glycosidic bond, with release of UDP as a reaction
product. To increase the solubility of the glycogen molecule and
create a greater number of non-reducing terminal glucose [C4]
residues elongated chains of glycogen are branched. A branching
enzyme transfers a segment of at least 4 glucose units from the
end of a glycogen chain to the C6 hydroxyl of a glucose residue
of glycogen to yield a branch with an a-1,6 linkage.
When the cell requires glucose, and exogenous glucose lacks,
glycogen is degraded (glycogenolysis). Glycogen phosphorylase cat-
alyzes glycogen breakdown via phosphorolytic cleavage of the
a-1,4 glycosidic bonds, releasing G1P as the reaction product.
However, glycogen phosphorylase is not able to disrupt the a-1,6
glycosidic linkages at branch points. Therefore, when 4 glucose
monomers remain before the branch point, the further degradation
of glycogen requires the intervention of the debranching enzyme
(amylo-a-1,6-glucosidase, 4-a-glucanotransferase [AGL]). AGL cat-
alyzes two different reactions: (1) The transferase activity transfers
three glucose monomers from a 4-residue limit branch to the end
of another glycogen chain, reducing the limit branch to a single
glucose monomer. (2) The a-1,6 glucosidase activity catalyzes
hydrolysis of the a-1,6 linkage, yielding one free glucose residue
and removing the branch point [54].
An altered turnover of glycogen with high levels of glycogen
stores (a reserve to be used as a glucose source for anaerobic gly-
colysis under transient energy shortage conditions) are observed
in several cancer cells models (breast, kidney, uterus, ovary, skin,
and brain cancer cell lines, including also urothelial cancer),
emerging as a metabolic survival pathway [55,56].
The intracellular increase in glycogen accumulation occurs
under hypoxic conditions, and seems to be dependent on the
hypoxia-inducible factor 1 (HIF-1). The transcription factor HIF-1
promotes tumor cell proliferation altering cell metabolism, not
only favoring a metabolic shift from oxidative phosphorylation to
glycolysis and lactic acid production, but also stimulating glycogen
synthesis and accumulation by the induction of phosphoglucomu-
tase activity [57], glycogen synthase 1 [58], protein phosphatase
1 regulatory subunit 3C gene (PPP1R3C) [59], and other proteins
involved in glycogen synthesis. Therefore, glycogen storage repre-
sents an adaptive survival mechanism to overcome microenviron-
ment glucose and oxygen paucity, hence assuring tumor cell
proliferation and survival [57,58].
Fig. 1. Mir-21 regulation, in brief. TGFß1 induces the phosphorylation of SMAD2/3 by TGFßR1 and TGFßR2 receptors, which in turn, leads to up-regulation of miR-21 in
human breast cancer cell lines. In particular, SMAD2/3 bind miR-21 promoter and enhance its transcription. MiR-21, which transcription is enhanced also by STAT3, represses
important tumor suppressor genes including PTEN, tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4), and maspin (also SERPINB5).
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correlate with proliferation rate via modulation of glycogen phos-
phorylase activity. Maximal activity of glycogen phosphorylase
(causing low intracellular glycogen content) coincided with the
period of high division rate. Conversely, when the rate of tumor cell
division decreased, phosphorylase activity consensually decreased
leading to increased glycogen levels [55,60]. The high proliferation
rate of cancer cells needs augmented macromolecule synthesis
(mainly RNA, DNA and fatty acids), which requires an increased
demand for glucose to be shunted into ribose-phosphate and
acetyl-CoA precursor synthesis pathways. Glycogen breakdown
(releasing glucose) represents therefore a rapid energy source. Evi-
dence of a key role of glycogen in promoting cancer cell survival
under hypoxic conditions comes from preclinical data of a glyco-
gen phosphorylase inhibitor (CP-320626), which impairs theglycogen homeostasis by blocking glycogenolysis, reducing the
availability of the energy substrate glucose with subsequent arrest
of proliferation and increase in apoptosis of pancreatic cancer cells
[61].
Glycogen metabolism pathway plays a robust role also in blad-
der cancer development. Therefore, a deep understanding of the
glycogen metabolism and its metabolic alterations in urothelial
malignancies represents a key topic of cancer research, hypothesiz-
ing novel effective targets for therapy [62].
Several aberrations of the glycogen metabolic pathway have
been observed in urothelial tumors:
The overexpression of GLUT-1
Neoplastic cells distinctively display accelerated metabolism,
high glucose requirement, and increased glucose intake. The
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membrane transport of glucose, which is mediated by facilitative
glucose transporter (GLUT) proteins. Increased expression of GLUT
proteins (mainly GLUT-1 and/or GLUT-3) in cancer cells leads to
augmented intracellular glucose up-take, thus supporting cells
proliferation in human tumors [6].
Interestingly, GLUT-1 is selectively expressed in neoplastic
urothelial tissue (of both non-muscle invasive and muscle-
invasive bladder carcinoma), but not in normal urothelium or
benign papillomas of the bladder [63,64]. Moreover, the grade of
GLUT-1 expression correlates with bladder cancer progression
(grater GLUT-1 expression in muscle-invasive and high nuclear
grade cancers compared to superficial and low-grade tumors)
[64]. Finally, the overexpression of GLUT1 seems to confer poor
prognosis, correlating with worse overall survival, supporting its
potential role as a marker of biologically aggressive disease [11,65].
The loss of the tumor suppressor glycogen debranching enzyme AGL
A recently published analysis used human xenograft models of
bladder cancer and a genome-wide lentiviral short-hairpin RNA
(shRNA) library coupled with next-generation sequencing (NGS)
to discover in vivo novel genes functionally important in bladder
carcinogenesis. AGL was identified as a crucial player in negatively
regulating bladder cancer growth. Indeed, loss of AGL was strongly
associated with tumor growth and clinically aggressive disease
[66].
AGL contributes to complete breakdown of glycogen to glucose-
6-phosphate (glycogenolysis) removing branch points. Tumor cells
with AGL loss showed a reduced content of normal glycogen, and a
reciprocal accumulation of abnormally branched glycogen (such as
limit dextrin) [66]. Analogous biochemical sequelae are observed
in glycogen storage disease type III (GSDIII – Cori disease), an auto-
somal recessive hereditary syndrome marked by germline muta-
tion of AGL, compromising glycogen breakdown with subsequent
intracellular storage of abnormal limit dextrin. Impaired liver func-
tion, cardiomyopathy and rapid muscular exhaustion are clinical
consequences of the accumulation of abnormal glycogen in the
liver, heart and skeletal muscle, respectively [67].
However, the precise mechanism by which AGL depletion acts
as tumor suppressor is not yet entirely understood. It has been
supposed that the role of AGL in promoting tumor growth cannot
be attributed to its enzymatic activities in glycogenolysis.
AGL loss impairs glycogen breakdown and favors bladder can-
cer growth via independent mechanisms. Indeed, in vitro inhibition
of glycogenolysis through depletion of glycogen phosphorylase
(another crucial enzyme in the glycogen breakdown process) does
not affect (induce) bladder cancer cell proliferation, suggesting that
the glycogenolysis inhibition is not a necessary step of bladder
cancerogenesis and strengthening the absolute independence of
the pro-oncogenic role of AGL-loss from glycogenolysis. Moreover,
enzymatically inactive AGL mutants (lacking both the glucotrans-
ferase and glucosidase activities) preserve the tumor-suppressive
function of wild-type AGL in bladder cancer models. Indeed, blad-
der cancer cells transduced with shRNA against AGL (shAGL)
showed AGL depletion and subsequent enhanced proliferation.
Conversely, transfection with enzymatically inactive AGL variants
(and shAGL-insensitive wild-type AGL) reversed the increased
tumor growth observed with AGL loss. These data demonstrate
that loss of AGL promotes bladder cell growth independently from
reduced glycogen breakdown. Inhibition of glycogenolysis is not
the key driver of bladder cancer growth. Thus, the enzymatic activ-
ities of AGL are not required for its growth-suppressive function in
bladder carcinogenesis. Increased tumor cell proliferation observed
with AGL loss is not correlated to its role in glycogenolysis [66].
Therefore, we should assume that AGL carries unknown non-
enzymatic properties (not yet entirely known) that influencetumor growth. Among non-metabolic functions, it seems that
AGL loss leads to a metabolic reprogramming of cancer cells.
In particular, AGL loss reprograms the serine-to-glycine conver-
sion pathway. In fact, cells with diminished AGL levels exhibit
increased glycine amount, but unchanged concentrations of the
glycine precursor (serine) [66]. Augmented mitochondrial glycine
biosynthesis strongly correlates with rapid cancer cells prolifera-
tion [68]. AGL depletion determines augmented levels of the
serine-to-glycine enzyme serine hydroxymethyltransferase-2
(SHMT2), resulting in an increased glycine synthesis and purines
synthesis (for which glycine is a precursor), thus supporting
nucleotides synthesis required for DNA synthesis and subsequent
cancer cells proliferation in vitro and in vivo. Therefore, AGL loss
induces tumor growth via promoting increased glycine-driven syn-
thesis of nucleotides from non-glucose (serine) sources [66].
In summary, AGL loss causes high SHMT2 expression, and
consequently increased glycine-dependent nucleotide synthesis
leading to bladder cancer growth.
Additional metabolic pathways are compromised by AGL loss.
In particular, an augmented glucose uptake, due to increased
GLUT-1 translocation to the membrane, does not result in
increased glucose-to-lactate conversion (which is, on the contrary,
decreased), suggesting a glucose shift towards metabolic pathways
involved in the synthesis of macromolecules required for cell pro-
liferation [66]. Moreover, AGL depleted-cells have increased ana-
bolic processes, including increased protein synthesis due to
increased amino acids (alanine, aspartate, and glutamate) forma-
tion, consistent with an increased contribution of glucose from gly-
colytic and tricarboxylic acid cycle (TCA) flux followed by
transamination of the intermediates oxaloacetate, pyruvate, and
a-ketoglutarate. Similarly, in AGL depleted-cells, glucose repre-
sents an important carbon source for nucleotide ring and ribose
moiety de novo synthesis (increased glycine synthesis from glu-
cose), both necessary for RNA and DNA formation in proliferating
cells, via an increased flux through the pentose phosphate pathway
and increased incorporation of ribose into purine and pyrimidine
nucleotides [66].The increased activity of the tumor promoter enzyme glycogen
phosphorylase
Glycogen turnover undergoes significant alterations in cancer
cells, breaking the physiological equilibrium between synthesis
and breakdown, thus resulting in temporal changes of intracellular
glycogen concentration. Initially, a rapid hypoxia-driven induction
of glycogen synthase leads to an early glycogen storage. The accu-
mulation of glycogen promotes cancer cell survival as an adaptive
way to ensure an energy source in a status of glucose and oxygen
deprivation [57,58]. Subsequently, an increase of glycogen phospho-
rylase activity (mainly of the liver isoform of glycogen phosphorylase
[PYGL]) causes a slow decline of glycogen stores, raising the pro-
portion of glucose that is diverted to the pentose phosphate and
de novo fatty acid synthesis pathways, which are necessary to sup-
port elevated synthesis of macromolecules (nucleotides, amino
acids, and fatty acids) required by rapidly proliferating cells. There-
fore, glycogen phosphorylase plays a crucial role in cancer cell biol-
ogy, regulating the glucose availability to sustain tumor cell
proliferation and prevent premature senescence [69]. Depletion
(or pharmacological inhibition [61,70]) of glycogen phosphorylase
determines glycogen accumulation, limits the synthesis of nucleo-
tides (decreasing the glucose substrate source for the pentose
phosphate pathway), induces premature senescence by increasing
ROS levels, and impairs tumor cells proliferation due to p53-
dependent growth arrest [69,71]. Glycogen phosphorylase might
therefore be a possible therapeutic target for inhibition in bladder
cancer with overactive glycogen and glucose metabolism.
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Alterations in lipid metabolism are involved in bladder carcino-
genesis [72].
Lipids are molecules composed of fatty acids insoluble in polar
solvents (hydrophobicity) and soluble in apolar solvents
(lipophilicity). Physiologically, lipids can be divided into storage
lipids (with protective and energy functions – triglycerides) and
structural lipids (the main component of cell membranes and
responsible of inter-cellular transporting systems and intra-
cellular signal transmission – phospholipids, glycolipids,
cholesterol).
The high energy yield of fatty acids is the result of oxidative
demolition processes (lipid breakdown), which consist of two main
phases: (1) the mitochondrial b-oxidation – a catabolic process
entailing the gradual oxidative cleavage of two-carbon fragments
in the form of acetyl-CoA from fatty acids previously activated to
acyl-CoA. (2) The subsequent oxidation of acetyl-CoA to carbon
dioxide by the citric acid cycle (TCA/Krebs cycle), and then by
the mitochondrial electron transport chain to release energy.
While breakdown of lipids takes place in the inner space of the
mitochondria (matrix), their activation to acyl-CoA occurs outside
of the internal mitochondrial membrane. Carnitine is essential in
mediating the transport of acyl groups across the mitochondrial
inner membrane. The enzyme carnitine palmitoyltransferase I
(located on the outer surface of the inner mitochondrial mem-
brane) catalyzes the transfer of acyl groups to the hydroxyl group
of carnitine. Unlike acyl-CoA molecules (insoluble), acyl-carnitines
are able to cross the inner mitochondrial membrane (by carnitine
translocase), reaching the mitochondrial matrix. Here, the acyl
groups are transferred to the mitochondrial CoA-SH by carnitine
palmitoyltransferase II (localized on the inner surface of the inner
mitochondrial membrane), with acyl-CoA and carnitine as terminal
products.
Several studies have suggested a possible carcinogenic role of
elevated levels of carnitine in bladder cancer. Metabolomic profil-
ing revealed potential urine metabolites altered in bladder cancer
progression (including carnitine), therefore helpful distinguishing
bladder cancer from normal controls and also non-muscle from
muscle-invasive bladder cancer [73]. Jin and Colleagues used
high-performance liquid chromatography–quadrupole time-of-
flight mass spectrometry (HPLC–QTOFMS) to identify different
urine metabolomic profiles that allow distinguishing bladder can-
cer patients from healthy control groups, and muscle invasive from
non-muscle-invasive bladder cancer patients. Several cancer-
specific metabolites were identified, including carnitine and acyl-
carnitines (carnitine, isovalerylcarnitine, glutarylcarnitine,
octenoylcarnitine, and decanoylcarnitine). Moreover, bladder can-
cer groups (and particularly muscle-invasive tumors) expressed
significantly higher levels of carnitine palmitoyltransferase 1A
(CPT1A) than control tissues. These results suggest a key role of
fatty acid oxidation in promoting bladder cancer development
and progression [74]. Similar findings derived from metabolomic
profiling analysis that identified urinary carnitine C9:1 (combined
with component I) as a viable biomarker for discriminating bladder
cancer patients [75].
Under conditions of limited glucose availability (i.e. fasted state
or rapidly proliferating cancer cells), fatty acid b-oxidation
becomes the primary energy source. However, when the amount
of acetyl-CoA generated in b-oxidation exceeds its utilization in
the Krebs cycle (for lack of oxaloacetate – derived from glucose
via pyruvate), ketogenesis take place. Acetyl-CoA is then used in
biosynthesis of ketone bodies (including acetoacetate, b-
hydroxybutyrate, and acetone), to make available the CoA required
for the further beta-oxidation of fatty acids.Elevated lipids and acetoacetate levels have been detected in
serum samples of bladder cancer patients using H nuclear mag-
netic resonance (NMR)-based metabolomics analysis [76]. Simi-
larly, an NMR-based metabolite profiling analysis of canine
xenograft model (exploiting analogies between naturally-
occurring canine transitional cell bladder carcinoma and human
invasive bladder cancer) demonstrated high levels of acetone and
b-hydroxybutyrate in invasive bladder cancer urine samples com-
pared with healthy controls [77].
Therefore, high levels of ketone bodies could reflect increased
activity of fatty-acid b-oxidation pathway instead of active glycol-
ysis in bladder cancer cells, leading to increase in TCA activity and
oxidative phosphorylation, and subsequent excess amounts of
acetyl-CoA that is diverted towards ketogenesis.
Another demonstration of the increase of fatty acids beta-
oxidation as an energy source in proliferating tumor cell derived
from the identification of lower triglycerides levels (source of fatty
acids) in patients with bladder cancer compared to healthy con-
trols [78].
In contrast to lipolysis, when glucides exceeds immediate
energy requirements, and after saturation of tissue glycogen
deposits, glucose (acetyl-CoA) is converted into storage lipids (lipo-
genesis). Lipogenesis encompasses both fatty acid and triglyceride
synthesis (where fatty acids are esterified with glycerol). Through
fatty acids biogenesis and triglyceride synthesis, the surplus
energy can be efficiently stored in the form of fats.
Fatty acid synthesis is catalyzed by several enzymes organized
in a single multienzyme complex, termed fatty acid synthase
[FASN]. FASN catalyzes the NADPH-dependent synthesis of palmi-
tate from acetyl-CoA and malonyl-CoA, thus mediating the conver-
sion of glucides into fatty acids. Triglyceride synthesis originates
from activated fatty acids (acyl-CoA) and glycerol-3-phosphate
(produced by reduction of dihydroxyacetone phosphate [DHAP] –
a glycolysis intermediate – by the glycerol-3-phosphate
dehydrogenase) through two acylation reactions. Therefore, the
glycerol-3-phosphate dehydrogenase enzyme acts as a bridge
between carbohydrates and lipids metabolism.
Tumor cells can reactivate de novo lipid synthesis, highlighting
the potential role of lipogenesis in cancer pathogenesis [79]. Lipol-
ysis, in fact, provides lipids (essential constituents of cell mem-
branes) to proliferating cancer cells.
FASN over-expression seems to play a crucial role in BC devel-
opment (being associated with tumor cell survival and migration,
high histologic grade, tumor recurrence, and resistance to
chemotherapy) [80–82]. Therefore, blocking FASN may represent
a novel targeted-therapy strategy for BC [80,81].
Additionally, glycerol-3-phosphate dehydrogenase activity has
been reported to be up-regulated in bladder cancer, supplying
glycerol-3phosfate for lipid biosynthesis [83].
Various metabolites involved in lipid metabolism seem to be
altered (up-regulated) in BC patients, suggesting a deregulation
of physiological control mechanisms, and reinforcing a potential
pro-carcinogenic action of lipid metabolism pathways.
A metabolomics analysis with liquid chromatography/mass
spectrometry (LC/MS) identified increased urine concentrations
of free fatty acids (oleic and palmitic acids) in BC samples [73].
Urine metabolites related to lipid metabolism seem to be robust
biomarkers to differentiate bladder cancer from non-cancer con-
trols, therefore representing potential non-invasive adjunct diag-
nostic to cystoscopy for early diagnosis of bladder cancer and
recurrent disease management. A comprehensive global metabolo-
mics profiling analysis of urine revealed 3 metabolites associated
with lipid metabolism, palmitoyl sphingomyelin, arachidonate,
and phosphocholine significantly elevated in bladder cancer
patients [84].
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in the phospholipids (especially phosphatidylethanolamine, phos-
phatidylcholine, and phosphatidylinositides) of cells membranes,
particularly abundant in the brain, muscles, and liver. Increased
arachidonate levels can derive from augmented release of free fatty
acids from phospholipids either in the tumor or in adjacent tissue.
Sphingomyelin is a key component of the outer plasma cell mem-
branes, whose cleavage (by neutral sphingomyelinases) generates
both phosphocholine and ceramide. Phosphocholine, in turn, is a
constituent of both glycerophospholipids and sphingomyelin. Aug-
mented urine levels of palmitoyl sphingomyelin and phospho-
choline may suggest a higher tumor cell proliferation rate with
increased lipid membrane remodeling, leading to increased urine
shedding of palmitoyl sphingomyelin and subsequent upregulation
of sphingomyelinases activity with augmented choline phosphate
in the urine of bladder cancer patients [84].
Analogous findings came from a study using high-resolution
magic angle spinning nuclear magnetic resonance (HR-MAS
NMR) and gas chromatography–mass spectrometry (GC–MS)
methods, which also demonstrated the up-regulation of choline-
containing compounds (choline, phosphocholine and glycerophos-
phocholine) in bladder patients (17 cases of Ta-T1 lesions and 16
muscle-invasive tumors) compared with benign controls (26 sub-
jects), but no significant difference was identified between super-
ficial and muscle-invasive tumors [78].
Similarly, Lin et al. demonstrated increased by comprehensive
LC–MS-based method (which utilizes both reversed phase liquid
chromatography [RPLC] and hydrophilic interaction chromatogra-Fig. 2. Metabolic pathwaphy [HILIC] separations) increased serum levels of phosphatidyl-
choline in patients with bladder cancer [85].
Elevated serum levels of malonate were found in high-grade
bladder cancer patients compared to low-grade tumors and
healthy controls [86]. Malonate level depend on the amount of
malonyl-CoA. Malonyl-CoA controls the metabolism of acyl-CoA,
and then of fatty acids synthesis. It inhibits the rate-limiting step
in beta-oxidation of fatty acids by inhibiting acyl-CoA: carnitine
acyl transferase, precluding acyl groups from associating with car-
nitine, thereby preventing fatty acid from entering within the
mitochondria (where fatty acid oxidation and degradation occur)
and inhibiting the beta-oxidation and ketogenesis.
In addition, Pasikanti et al. demonstrated by urinary metabo-
typing using two-dimensional gas chromatography time-of-flight
mass spectrometry (GC  GC–TOFMS) down-regulation of glycerol
(end product of triglycerides hydrolysis) in bladder cancer com-
pared with non-cancer patients [87].
In conclusion, in healthy subjects, the dynamic equilibrium of
lipid metabolism results from the balance between lipid break-
down (fatty acids b-oxidation to satisfy the energy requirements)
and lipid synthesis. Conversely, dysregulation of lipid metabolism
(altered fatty acid transportation, b-oxidation, or synthesis) might
be involved in the pathogenesis of bladder cancer.
Discussion
Metastatic bladder cancer is still considered a disease orphan
of effective treatments. The current standard treatment –ys in bladder cancer.
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median survival in these patients of about 12–14 months.
Many genetic and epigenetic alterations are involved in BC
development, progression, and metastasization.
However, unlike other tumor types (breast, melanoma, colorec-
tal cancer, lung adenocarcinoma), no effective molecular targets for
therapy and no biomarkers with a predictive value have yet been
identified in bladder cancer. Alterations in energy metabolism rep-
resent a hallmark of cancer, providing potential therapeutic targets
(Fig. 2). To date, as reported in Table 1, different molecularly tar-
geted agents are under evaluation. Recently, a complex analysis
that integrated data of metabolic alterations (involving amino acid,Table 1
Novel drugs in development in patients with bladder cancer (www.clinicaltrials.gov). E
mAb = monoclonal antibody; mTORc1 = mammalian target of rapamycin complex 1; PD
TKI = Tyrosine Kinase Inhibitor; VEGFR = Vascluar Endothelial Growth Factor Receptor.
Agent Trial ID
number
Phase Description Design
Erlotinib NCT02169284 II EGFR Tyrosine Kinase
Inhibitor
Erlotinib v
Afatinib NCT02122172 II Irreversible dual EGFR/HER2
inhibitor
Patients w
Neratinib NCT01953926 II Pan-HER inhibitor Patients w
or HER3 m
Trastuzumab NCT01828736 II Anti-HER2/neu receptor mAb Trastuzum
urothelial
Margetuximab
(MGAH22)
NCT01148849 I Anti-HER2 mAb Patients w
Dovitinib
(TKI258)
NCT01732107 II FGFR and VEGFR TKI Patients w
mutations
BAY1163877 NCT01976741 I Pan-FGFR inhibitor Patients w
Bevacizumab NCT00942331 III Anti-VEGF mAb Cisplatin a
NCT00268450 II Cisplatin a
locally adv
NCT00506155 II In combina
neoadjuva
Sunitinib NCT01118039 II VEGFR, PDGFR, c-kit TKI Locally rec
NCT00794950 II BCG follow
Sorafenib NCT01844947 I VEGFR and PDGFR and RAF
kinases TKI
In addition
Pazopanib NCT01265940 I/II VEGFR, FGFR, PDGFR and
c-KIT TKI
Advanced
NCT01031875 II Patients w
treatment
NCT01622660 II In combina
urothelial
NCT01108055 II In combina
Trebananib
(AMG386)
NCT01907308 II Selective Ang1/2-
neutralizing peptibody
In combina
platinum-c
Everolimus NCT01259063 I/II mTORc1 inhibitor Everolimus
in situ of t
NCT01215136 II In combina
carcinoma
Temsirolimus NCT01827943 II mTORc1 inhibitor Second-lin
Buparlisib NCT01551030 II Pan-class I selective PI3K
inhibitor
Patients w
Alisertib NCT02109328 II Selective inhibitor of Aurora
Kinase A
In combina
pretreated
OGX-427 NCT01454089 II Antisense oligonucleotide
targeting Hsp27 mRNA
OGX-427 i
tumors
NCT01780545 II OGX-427 i
bladder tu
Celecoxib NCT00006124 IIb/III COX2 inhibitor Celecoxib i
MPDL3280A NCT02108652 II Anti-PD-L1 monoclonal
antibody
Patients w
LDE225 NCT02002689 II Potent and selective SMO
antagonist
Patients wnucleotides, lipids and glycolysis pathways) from targeted
mass-spectrometry with transcriptome data from TCGA identified
a molecular signature of 30 metabolic genes, whose the up-
regulation was associated with tumor progression and poor prog-
nosis [88]. This integrated metabolic/transcriptomic pathway
signature linked with BCa progression demonstrates once again
the crucial role of metabolic alterations in BC development and
progression.
We extensively outlined the crucial role of anaerobic glycolysis
in providing adequate energy supplies, but also in ensuring inter-
mediate metabolic precursors for the biosynthesis of non-glucidic
compounds (amino acids and lipids). Numerous inhibitors ofGFR = epidermal growth factor receptor; FGFR = Fibroblast Growth Factor Receptor;
GFR = Platelet-derived Growth Factor Receptor; TCC = Transitional Cell Carcinoma;
s. placebo as neoadjuvant therapy in patients undergoing surgery
ith urothelial cancer refractory to chemotherapy
ith solid tumors (including bladder cancer) harboring somatic human EGFR, HER2
utations or EGFR gene amplification
ab in combination with gemcitabine and platinum for advanced or metastatic
carcinoma
ith HER2-positive carcinomas including bladder tumors
ith Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma with FGFR3
or overexpression
ith lung or bladder cancer
nd gemcitabine with or without bevacizumab as first-line therapy
nd gemcitabine followed by surgery, bevacizumab and paclitaxel in patients with
anced tumors removable by surgery
tion with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) as
nt therapy
urrent, locally advanced, unresectable, or metastatic urinary tract cancer
ed by sunitinib for the treatment of high risk NMI-BC
to vinflunine in metastatic TCC of the urothelial tract
urothelial cancer of bladder after failure of platinum-containing therapy
ith metastatic urethral or bladder cancer that has relapsed or not responded to
tion with gemcitabine chemotherapy naïve patients with advanced/metastatic
carcinoma ineligible for cisplatin-based chemotherapy
tion with weekly paclitaxel in refractory urothelial cancer
tion with docetaxel for advanced urothelial carcinomas after failure of a
ontaining regimen
and intravesical gemcitabine in BCG-refractory primary or secondary carcinoma
he bladder
tion with paclitaxel for cisplatin-ineligible patients with advanced urothelial
e therapy in for patients with advanced bladder cancer
ith metastatic TCC
tion with paclitaxel vs. paclitaxel alone in patients with chemotherapy-
urothelial cancer
n combination with gemcitabine and cisplatin in patients with advanced bladder
n combination with docetaxel vs. docetaxel alone in patients with advanced
mors
n preventing recurrence of superficial urothelial bladder cancer
ith locally advanced or metastatic urothelial bladder cancer
ith PTCH1 or SMO mutated tumors including bladder cancer
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have been tested in bladder cancer patients, and to date there is no
evidence of a clinical benefit that supports their use in clinical
practice.
Glucose transporters and several glycolytic enzymes involved in
tumorigenesis can be targets for inhibition in cancer treatments. In
particular, GLUT inhibitors (the natural phenol derivative Phloretin
[89], or the small molecule WZB117 [90]) exert anticancer effects
by blocking tumor cells growth and/or sensitizing the cancer cells
to chemotherapy. The glycolytic enzyme HK can be selectively
blocked by several compounds, including lonidamine, 2-deoxy-D-
glucose, and 3-bromopyruvate, resulting in promising antitumor
effect when combined with chemotherapy [91]. Moreover, LDH-A
and PFKFB3 are promising targets for inhibition in cancer treat-
ments [26,92,93].
Glycogen metabolism represents another deregulated pathway
with a major role in BC. A potential pharmacological target of this
pathway is the enzyme glycogen phosphorylase, leading to the
development of several glycogen phosphorylase inhibitors. CP-
320626, CP-91149, and flavopiridol block glycogenolysis, reducing
the availability of glucose to be recycled into the PPP and lipid syn-
thesis, with subsequent arrest of proliferation and increase in
apoptosis of pancreatic cancer cells [61,94–96]. The mTOR-
inhibitor everolimus has been evaluated in metastatic BC patients
progressing after failure of platinum-based chemotherapy, sug-
gesting a potential biological activity in a subgroup (yet to be
determined) of patients with urothelial cancer. These studies high-
light the need to preselect patients based on molecular cancer phe-
notype to maximize benefit from targeted agents like everolimus
(i.e. PTEN loss might be associated with everolimus resistance)
[97,98].
Certainly the way is still long. Effort are required to understand
the metabolic abnormalities underlying bladder carcinogenesis,
identify the best therapeutic targets and develop therapeutic mole-
cules that combine their anti-tumor effect with an adequate
toxicity profile.
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